NANJING KING FRIEND
GenericsNANJING KING FRIEND is a generic drug manufacturer focused on Metabolic, Cardiovascular.
NANJING KING FRIEND's Key Drugs
NANJING KING FRIEND's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).
NANJING KING FRIEND's Recent FDA Approvals
New NDA/BLA approvals for NANJING KING FRIEND over the last two years — novel drugs only, excluding generics and label supplements.
NANJING KING FRIEND's Therapeutic Areas
NANJING KING FRIEND's approved drugs and pipeline span 2 therapeutic areas, led by Metabolic and Cardiovascular. Weighted by commercial stage — approved drugs count most, then late-stage trials.
NANJING KING FRIEND's Top Competitors
NANJING KING FRIEND's closest competitors by therapeutic-area and drug-target overlap include Merck, Baxter, and Sanofi. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
NANJING KING FRIEND Pipeline Snapshot
Active clinical trials for NANJING KING FRIEND across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • Top drug revenue breakdown
- • Drug-level revenue analysis
Trial Catalysts
- • Metabolic pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling
Active (0)
Discontinued (0)
Company Info
- First Approval
- 2025-04-02
- Latest
- 2025-10-15
- Applications
- 2